Almac provides a wide range of biomarker solutions ranging from pre-clinical biomarker discovery to biomarker trial management, full companion diagnostic development and clinical test delivery from its clinical laboratory improvement amendments (CLIA) laboratory.
The company has a portfolio of proprietary discovery arrays and extensive experience and expertise working with formalin fixed paraffin embedded (FFPE) tissue.
Almac is uniquely placed to lead clients through the entire process of companion diagnostic development. Its Diagnostics’ Business Unit provides solutions ranging from pre-clinical biomarker discovery, through to full companion diagnostic development.
Companion diagnostic (CDx) development and commercialisation
Almac offers a comprehensive service for companion diagnostic developments supporting the pharmaceutical industry from discovery right through to commercialisation. It also has specific expertise and experience in the development of multiplex companion diagnostics.
CLIA assay development
Almac has extensive expertise in the development of Clinical Laboratory Improvement Amendments (CLIA) validated clinical assays both in terms of carrying out biomarker discovery to develop its own internal pipeline and developing them into clinical assays on a client’s behalf.
Almac also has extensive experience developing assays for early-stage trial enrichment studies. These are offered on a range of platforms from multiple tissue types with particular expertise in formalin fixed paraffin embedded (FFPE) tissue.
Retrospective sample collection
Almac’s retrospective sample collection service is a unique offering that allows biomarker discovery and development studies to be carried out on completed trials, even those that did not have a biomarker component.
Almac offers expert services in biomarker discovery with more than ten years’ experience in the discovery of clinically applicable biomarkers both in their own internal research and development and in services to our clients.
RUO assay development
Almac’s assay development services are not limited to predictive markers for clinical use. It also offers services in the development of research or retrospective use (RUO) assays on a range of platforms.
Biomarker laboratory services
Almac’s laboratory service is just one of the ways it can customise a solution to meet a client’s needs. With its state-of-the-art laboratories, expert consultants and data interpretation services, Almac is able to support its clients at every stage of research.